Browse diseases

…Background Patients with head and neck squamous cell carcinoma (HNSCC), particularly the human papillomavirus negative (HPV −) subset,…

…Background Head and neck cancer remains the 6th most common cancer globally, with patients ofte…

…B response in eight new and diverse clinical cohorts; including melanoma, NSCLC, breast, renal, bladder, and HNSCC; with a mean AUC of 0…

…l improve HNSCC ICI prognostic models.Methods Patients with R/M HNSCC receiving ICI (n = 114) were recruited from Dana-Farber Cancer …

…ature.Methods Explants generated from fresh surgically resected HNSCC samples (n=67) collected from the consented patients were cultu…

…Background Immunotherapy (IO) has revolutionized treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), but not all patients benefit. Despite advances in unde…

…provides a basis for the improvement of immunotherapies against solid tumors by manipulating DNA repair.References Wherry EJ, Kurachi M. Mol…

…hausted CTL population (CD8+PD1+); the target for nivolumab, in CRC (n=4), RCC (n=2) and CaBr (n=3), Nivolumab treatment induced in…

…ciates with an immune activated ‘hot’ tumor microenvironment.In melanoma, elevated baseline activated CD8+ central memory T cells and pr…

…heckpoint blockade (ICB) therapy has shown promise for treating head and neck squamous cell carcinoma (HNSCC), but only a subset of patients exhibit a meaningful response. H…

… ( NCT04183166) evaluating TG4050 in resected, locally advanced HNSCC patients after (chemo)radiation, we showed that patients random…

… IL-27, NO, VIP, VDR, TRAIL, and the Ca types were NSCLC, SCLC, HNSCC, Melanoma, GBM, Pancreatic, Bladder, Gastric, Prostate, Breast,…